• Users Online: 34155
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Year : 2022  |  Volume : 13  |  Issue : 4  |  Page : 176-182

Management of acquired hemophilia: Consensus recommendations for the United Arab Emirates practitioners

1 Department of Hematology/Oncology, Dubai Hospital, Al Ain, UAE
2 Department of Hematology/Oncology, Saudi German Hospital, Al Ain, UAE
3 Department of Hematology/Oncology, Tawam Hospital, Al Ain, UAE
4 Department of Hematology/Oncology, King's College Hospital, Al Ain, UAE
5 Department of Hematology/Oncology, Sheikh Shakhbout Medical, Al Ain, UAE
6 City Abu Dhabi, Pediatric Hematology/Oncology Department, Tawam Hospital, City Abu Dhabi, Al Ain, UAE

Correspondence Address:
Prof. Mahmoud Marashi
Dubai Hospital, Dubai
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/joah.joah_25_22

Rights and Permissions

Acquired hemophilia A (AHA) is a rare autoimmune condition characterized by spontaneous antibodies formation against coagulation factor VIII (FVIII). In the United Arab Emirates (UAE), the treatment paradigm of AHA varies, leading to heterogeneous patient outcomes. Because AHA cases often present to clinical practitioners with insufficient experience in the disease, diagnosis is sometimes delayed. This document aims to provide recommendations to clinical practitioners in the UAE to bridge the gap of heterogeneous practice in the clinical management of AHA. Structured literature searches in PubMed and Google Scholar with a three-stage Delphi method were conducted. Evidence suggests that prolonged activated partial thromboplastin time before surgery or coupled with acute or recent onset of bleeding is a hallmark of AHA. Treatment using bypassing agents is recommended in AHA patients with bleeding. Corticosteroids and rituximab with (out) a cytotoxic agent represent the first-line treatment in patients with FVIII: C <1 IU/dL. Second-line therapy involves agents not utilized in the first round of treatment. Thromboprophylaxis is recommended if FVIII: C has returned to normal levels. These recommendations are intended to improve the clinical practice and awareness of this disorder among hematologists and nonhematologists in the UAE and provide practical diagnosis and treatment advice.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded406    
    Comments [Add]    

Recommend this journal